The results of the trial demonstrated that BioThrax plus CPG 7909 generated antibody responses that were 6-fold higher than those generated by BioThrax alone (232µg/ml with BioThrax alone; 1465 µg/ml with BioThrax plus CPG 7909).
Additionally, BioThrax plus CPG 7909 speed up the time to reach the peak immune response seen following BioThrax vaccination by three weeks.
Emergent president and chief operating officer Daniel Abdun-Nabi said the Phase 1a data on BioThrax plus CPG 7909 add support to their hypothesis that the combination could have enhanced characteristics over BioThrax alone.